Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment

Arcellx Inc. (NASDAQ:ACLX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, the company delivered promising Pivotal Phase 2 study results of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma. The company is developing an anti-CD in partnership with Kite, a Gilead company unit, ahead of the planned 2026 commercial launch.

The trial results from the iMMagine-1 study underlined deep and durable responses with a predictable and manageable safety profile. No adverse effects such as Parkinsonism, cranial nerve palsies, or Guillain-Barré syndrome have been observed with anti-cello as part of the ongoing trials.

“These data are compelling and are an important advancement for patients living with multiple myeloma,” said Dr. Krina Patel, Associate Professor at the Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, and iMMagine-1 and iMMagine-3 clinical investigator.

Stifel has reiterated a Buy rating and a $127 price target, impressed by initial data from the Phase 3 MajesTEC-3 TRIAL. The results showed landmark progression-free survival and overall survival rates.

Arcellx, Inc. (NASDAQ:ACLX) is a clinical-stage biotech company developing innovative cell therapies for cancer and autoimmune diseases, using proprietary D-Domain technology (ddCAR) and the ARC-SparX platform to create safer, more controllable, and broadly accessible treatments, with a key focus on multiple myeloma and leukemia.

While we acknowledge the potential of ACLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.